Acute Coronary SyndromeTeleCorNCT04862026
Telemonitoring of Patients With Acute Coronary Syndrome
An observational study of Acute Coronary Syndrome, run by Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department at 1 site in Russia.
Trial summary
It is planned to enroll 950 patients in an open, prospective, randomized study to assess the impact of telemonitoring on the development of clinical events and improve the quality of life of patients with acute coronary syndrome. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Acute Coronary Syndrome
- How many people
- 950 participants
- Where
- 1 siteRussia
- Study dates
- 29 Apr 2021to 1 Jun 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with acute coronary syndrome who have undergone the hospital stage of treatment are included in the study at the time of discharge. And then, at the outpatient stage after randomization, the first group receives standard assistance together with telemonitoring support, the second group - standard offline medical assistance.
Who may be able to join
- Signed informed consent;
- Age 18 - 80 years old.
- Diagnosis:
- Acute myocardial infarction (I21.0, I21.1, I21.2, I21.3, I21.4, I21.9)
- Unstable angina (I20.0) Recurrent myocardial infarction (I22.0, I22.1, I22.8, I22.9)
Who cannot join
- Lack of technical equipment to connect to remote monitoring programs;
- Severe cognitive dysfunction - dementia leading to maladjustment in everyday life;
- Mental illness in the acute stage;
- Oncological diseases requiring radiation and chemotherapy during the period of this study, as well as the corresponding stages of T3-4N2-3M1;
- Lack of technical ability to take part in telemonitoring (do not have the skills to work on a smartphone, computer, tablet, there is no appropriate technical means);
- Participation in other clinical studies to assess the effectiveness of pharmacological drugs;
Show all 10Show fewer
- Infection with SARS-CoV-2 with laboratory confirmation during the period of this study;
- Acute coronary syndrome that developed in the hospital after surgery / intervention;
- The emergence during observation of the need for surgical (not counting myocardial revascularization) or chemotherapy treatment;
- Severe trauma (including craniocerebral) impeding observation according to the study protocol.
Trial locations and contacts
1 site in 1 country.
Russia1 site
City Clinical Hospital No. 13 of the Moscow City Health Department
Moscow, 115280
About this study
Official title: The Influence of Telemonitoring on the Development of Clinical Events and Improving the Quality of Life of Patients With Acute Coronary Syndrome (TeleCor)
It is planned to enroll 950 patients in an open, prospective, randomized study to assess the impact of telemonitoring on the development of clinical events and improve the quality of life of patients with acute coronary syndrome. The duration of the study is 365 days, of which 180 days are enrollment of patients, 180 days are observation. The study of patients will include the collection of anamnesis, assessment of the clinical status of patients using special questionnaires, data of objective, laboratory and instrumental examinations. The instrumental complex of the examination will include: electrocardiography (ECG), 6-minute walk test (6MWT), Holter ECG monitoring (HMECG), echocardiography, veloergometry (VEM), assessment of the actual nutrition Nutrilogic, autogeneration of an individual diet (Nutrilogic), weekly telemonitoring. Laboratory examination includes: biochemical blood test. The main objectives of the study are to study the effect of telemonitoring on mortality from cardiovascular diseases (CVD), as well as the number of readmissions for cardiovascular pathology in patients with ACS. The secondary endpoints of the study include quality of life as measured by the HeartQol questionnaire and adherence to ambulatory monitoring.
Read the detailed description
Purpose of the study: to study the effect of telemonitoring on the development of clinical events and improving the quality of life of patients with ACS.
Research objectives:
- Improving the effectiveness of medical care in patients who have undergone ACS: increasing the level of compliance of patients, increasing the level of medical awareness of patients, reducing the number of unmotivated requests for medical care, reducing the time to achieve the observed targets, reducing the proportion of complications, reducing the number of destabilizing conditions with further inpatient treatment, optimization of the workload on medical personnel.
- Creation of a unified methodology for remote observation using telemedicine technologies in patients with ACS.
- Creation of a unified model of remote nutrition correction in patients after ACS.
Number of volunteers: statistically equivalent groups by sex and age, 950 subjects (475 per group). The number of volunteers who completed the study was 712 subjects (75% of the total number of patients).
365 days: 6 months enrollment, 6 months follow-up.
Inclusion criteria:
- Signed informed consent;
- Age 18 - 80 years old.
- Diagnosis:
- Acute myocardial infarction (I21.0, I21.1, I21.2, I21.3, I21.4, I21.9)
- Unstable angina (I20.0) Recurrent myocardial infarction (I22.0, I22.1, I22.8, I22.9)
Exclusion criteria:
- Lack of technical equipment to connect to remote monitoring programs;
- Severe cognitive dysfunction - dementia leading to maladjustment in everyday life;
- Mental illness in the acute stage;
- Oncological diseases requiring radiation and chemotherapy during the period of this study, as well as the corresponding stages of T3-4N2-3M1;
- Lack of technical ability to take part in telemonitoring (do not have the skills to work on a smartphone, computer, tablet, there is no appropriate technical means);
- Participation in other clinical studies to assess the effectiveness of pharmacological drugs.
Exclusion criteria:
- Infection with SARS-CoV-2 with laboratory confirmation during the period of this study;
- Acute coronary syndrome that developed in the hospital after surgery / intervention;
- The emergence during the observation of the need for surgical (not counting myocardial revascularization) or chemotherapy treatment;
- Severe injuries (including craniocerebral), impeding observation according to the study protocol.
Primary endpoint (combined):
- a) Death from cardiovascular causes and / or b) Repeated hospitalizations for SS pathology
- The number of episodes requiring emergency or urgent care without hospitalization (calls to the emergency room for complaints from the cardiovascular system)
Secondary endpoints:
- Quality of life according to the HeartQol questionnaire.
- Commitment to outpatient monitoring - is determined by the number of participants who voluntarily left the study, by the percentage of results obtained - surveys in electronic form.
- Tolerance to physical activity (any increase in walking distance according to 6MWT, VEM according to indications).
Any decrease in body weight (weight, BMI) any decrease in waist circumference. The study of patients will include the collection of anamnesis, assessment of the clinical status of patients using special questionnaires, data of objective, laboratory and instrumental examinations. The instrumental complex of the examination will include: electrocardiography (ECG), 6-minute walk test (6MWT), Holter ECG monitoring (HMECG), echocardiography, veloergometry (VEM), assessment of the actual nutrition Nutrilogic, autogeneration of an individual diet (Nutrilogic), weekly telemonitoring. Laboratory examination includes: biochemical blood test.
Randomization by means of envelopes.
It is planned to create in advance a database of identification numbers (hereinafter - ID) in the amount corresponding to the planned set of patients (950 ID). Further, these numbers will be divided into two groups with an equal number of IDs in each:
- Outpatient observation with connection to the telemonitoring program - 475 ID
- Outpatient monitoring without connecting to the telemonitoring program - 475 ID Each ID number will be placed in an individual envelope and sealed. In accordance with the agreement on the number of patients to be included in the study, each specific healthcare facility will be provided with sealed envelopes in the required volume, taking into account the equal distribution of volunteers into 2 groups. After opening the envelope, the patient is assigned this ID, and the patient is assigned to the corresponding ID group.
- Conditions
- Acute Coronary Syndrome
- Keywords
- Acute coronary syndrome, telemonitoring
- Medical subject headings
- Acute Coronary Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Telemonitoring group | The telemonitoring group will be connected to electronic medical systems, through which medical workers will remotely assess clinical and emotional status, adherence to drug therapy, and carry out nutritional adjustments. | |
| Control group | Patients with standard administration. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Death or rehospitalizations Primary endpoint A
Death from cardiovascular causes and / or rehospitalizations for cardiovascular pathology
Measured: Upon completion, up to 6 months
Emergency or urgent care without hospitalization
The number of episodes requiring emergency or urgent care without hospitalization (calls to the ambulance for complaints from the cardiovascular system)
Measured: Upon completion, up to 6 months
Secondary outcomes (4)
Quality of life according to the HeartQol questionnaire.
Health-related quality of life, symptoms, and functional status make up patient-reported outcomes
Measured: Upon completion, up to 6 months
Commitment to outpatient monitoring
Commitment to outpatient monitoring - is determined by the number of participants who voluntarily left the study, by the percentage of results obtained - surveys in electronic form.
Measured: Upon completion, up to 6 months
Tolerance to physical activity
Tolerance to physical activity (any increase in walking distance according to 6MWT, VEM according to indications).
Measured: Upon completion, up to 6 months
Decrease in body weight
Any decrease in body weight (weight, BMI) any decrease in waist circumference.
Measured: Upon completion, up to 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Apr 2021
- Study start29 Apr 2021
- Primary completion6 Apr 2023
- Study completion1 Jun 2025 (estimated)
Why it stopped: Technical difficulties of the developer
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Coronary SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 950 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Sergey Morozov, Study director, Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04862026
- Sponsor's protocol ID
- 2021-1
- Acronym
- TeleCor
- Status last verified
- Apr 2023
- First submitted
- 14 Apr 2021
- Last updated
- 10 Apr 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Apr 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Influence of Telemonitoring on the Development of Clinical Events and Improving the Quality of Life of Patients With Acute Coronary Syndrome (TeleCor)
- ClinicalTrials.gov ID
- NCT04862026
- Acronym / sponsor ID
- TeleCor / 2021-1
- Conditions
- Acute Coronary Syndrome
- Keywords
- Acute coronary syndrome, telemonitoring
- Study type
- Observational
- Recruitment status
- SuspendedReason stopped: Technical difficulties of the developer
- Enrolment
- 950 participants (estimated)
- Lead sponsor
- Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care DepartmentUniversity, hospital or other
- Study start
- 29 Apr 2021 (actual)
- Primary completion
- 6 Apr 2023 (actual)
- Study completion
- 1 Jun 2025 (estimated)
- First posted
- 27 Apr 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
It is planned to enroll 950 patients in an open, prospective, randomized study to assess the impact of telemonitoring on the development of clinical events and improve the quality of life of patients with acute coronary syndrome. The duration of the study is 365 days, of which 180 days are enrollment of patients, 180 days are observation. The study of patients will include the collection of anamnesis, assessment of the clinical status of patients using special questionnaires, data of objective, laboratory and instrumental examinations. The instrumental complex of the examination will include: electrocardiography (ECG), 6-minute walk test (6MWT), Holter ECG monitoring (HMECG), echocardiography, veloergometry (VEM), assessment of the actual nutrition Nutrilogic, autogeneration of an individual diet (Nutrilogic), weekly telemonitoring. Laboratory examination includes: biochemical blood test. The main objectives of the study are to study the effect of telemonitoring on mortality from cardiovascular diseases (CVD), as well as the number of readmissions for cardiovascular pathology in patients with ACS. The secondary endpoints of the study include quality of life as measured by the HeartQol questionnaire and adherence to ambulatory monitoring.
Detailed description
Purpose of the study: to study the effect of telemonitoring on the development of clinical events and improving the quality of life of patients with ACS.
Research objectives:
- Improving the effectiveness of medical care in patients who have undergone ACS: increasing the level of compliance of patients, increasing the level of medical awareness of patients, reducing the number of unmotivated requests for medical care, reducing the time to achieve the observed targets, reducing the proportion of complications, reducing the number of destabilizing conditions with further inpatient treatment, optimization of the workload on medical personnel.
- Creation of a unified methodology for remote observation using telemedicine technologies in patients with ACS.
- Creation of a unified model of remote nutrition correction in patients after ACS.
Number of volunteers: statistically equivalent groups by sex and age, 950 subjects (475 per group). The number of volunteers who completed the study was 712 subjects (75% of the total number of patients).
365 days: 6 months enrollment, 6 months follow-up.
Inclusion criteria:
- Signed informed consent;
- Age 18 - 80 years old.
- Diagnosis:
- Acute myocardial infarction (I21.0, I21.1, I21.2, I21.3, I21.4, I21.9)
- Unstable angina (I20.0) Recurrent myocardial infarction (I22.0, I22.1, I22.8, I22.9)
Exclusion criteria:
- Lack of technical equipment to connect to remote monitoring programs;
- Severe cognitive dysfunction - dementia leading to maladjustment in everyday life;
- Mental illness in the acute stage;
- Oncological diseases requiring radiation and chemotherapy during the period of this study, as well as the corresponding stages of T3-4N2-3M1;
- Lack of technical ability to take part in telemonitoring (do not have the skills to work on a smartphone, computer, tablet, there is no appropriate technical means);
- Participation in other clinical studies to assess the effectiveness of pharmacological drugs.
Exclusion criteria:
- Infection with SARS-CoV-2 with laboratory confirmation during the period of this study;
- Acute coronary syndrome that developed in the hospital after surgery / intervention;
- The emergence during the observation of the need for surgical (not counting myocardial revascularization) or chemotherapy treatment;
- Severe injuries (including craniocerebral), impeding observation according to the study protocol.
Primary endpoint (combined):
- a) Death from cardiovascular causes and / or b) Repeated hospitalizations for SS pathology
- The number of episodes requiring emergency or urgent care without hospitalization (calls to the emergency room for complaints from the cardiovascular system)
Secondary endpoints:
- Quality of life according to the HeartQol questionnaire.
- Commitment to outpatient monitoring - is determined by the number of participants who voluntarily left the study, by the percentage of results obtained - surveys in electronic form.
- Tolerance to physical activity (any increase in walking distance according to 6MWT, VEM according to indications).
Any decrease in body weight (weight, BMI) any decrease in waist circumference. The study of patients will include the collection of anamnesis, assessment of the clinical status of patients using special questionnaires, data of objective, laboratory and instrumental examinations. The instrumental complex of the examination will include: electrocardiography (ECG), 6-minute walk test (6MWT), Holter ECG monitoring (HMECG), echocardiography, veloergometry (VEM), assessment of the actual nutrition Nutrilogic, autogeneration of an individual diet (Nutrilogic), weekly telemonitoring. Laboratory examination includes: biochemical blood test.
Randomization by means of envelopes.
It is planned to create in advance a database of identification numbers (hereinafter - ID) in the amount corresponding to the planned set of patients (950 ID). Further, these numbers will be divided into two groups with an equal number of IDs in each:
- Outpatient observation with connection to the telemonitoring program - 475 ID
- Outpatient monitoring without connecting to the telemonitoring program - 475 ID Each ID number will be placed in an individual envelope and sealed. In accordance with the agreement on the number of patients to be included in the study, each specific healthcare facility will be provided with sealed envelopes in the required volume, taking into account the equal distribution of volunteers into 2 groups. After opening the envelope, the patient is assigned this ID, and the patient is assigned to the corresponding ID group.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Telemonitoring group | – | –The telemonitoring group will be connected to electronic medical systems, through which medical workers will remotely assess clinical and emotional status, adherence to drug therapy, and carry out nutritional adjustments. |
| Control group | – | –Patients with standard administration. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with acute coronary syndrome who have undergone the hospital stage of treatment are included in the study at the time of discharge. And then, at the outpatient stage after randomization, the first group receives standard assistance together with telemonitoring support, the second group - standard offline medical assistance.
Key inclusion criteria (5 listed)
- Signed informed consent;
- Age 18 - 80 years old.
- Diagnosis:
Key exclusion criteria (10 listed)
- Lack of technical equipment to connect to remote monitoring programs;
- Severe cognitive dysfunction - dementia leading to maladjustment in everyday life;
- Mental illness in the acute stage;
- Oncological diseases requiring radiation and chemotherapy during the period of this study, as well as the corresponding stages of T3-4N2-3M1;
- Lack of technical ability to take part in telemonitoring (do not have the skills to work on a smartphone, computer, tablet, there is no appropriate technical means);
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Death or rehospitalizations Primary endpoint A
Time frame: Upon completion, up to 6 months
Death from cardiovascular causes and / or rehospitalizations for cardiovascular pathology
Emergency or urgent care without hospitalization
Time frame: Upon completion, up to 6 months
The number of episodes requiring emergency or urgent care without hospitalization (calls to the ambulance for complaints from the cardiovascular system)
4 secondary outcomes
Quality of life according to the HeartQol questionnaire.
Time frame: Upon completion, up to 6 months
Commitment to outpatient monitoring
Time frame: Upon completion, up to 6 months
Tolerance to physical activity
Time frame: Upon completion, up to 6 months
Decrease in body weight
Time frame: Upon completion, up to 6 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Apr 2023.
- Individual participant dataSharing planned: No
Related trials for Acute Coronary Syndrome
Recruiting
CT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes
Coronary Artery Disease, Chest Syndrome
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
RecruitingPhase 4
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
Acute Coronary Syndromes, STEMI
Recruiting
AI-Assisted Interpretation of Cardiac CT in the Emergency Department
Chest Pain, Acute Coronary Syndrome
Enrolling by invitation
Optical Coherence Tomography in Acute Vessel Evaluation
Ischemic Heart Disease, Ischemic Coronary Artery Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sergey Morozov study director
Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Coronary Syndrome, run by Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department at 1 site in Russia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: paused, as of the sponsor's last update on 10 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Death or rehospitalizations Primary endpoint A (time frame: Upon completion, up to 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Apr 2023.